AflacST1901: Peds WP1066
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Brain Metastases
- Brain Tumor
- Medulloblastoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 3 years and 25 years
- Gender
- Both males and females
Description
The goal of this clinical research study is to find the highest tolerable dose of WP1066 that can be given to pediatric patients with recurrent (has returned after treatment) cancerous brain tumors or melanoma that has gotten worse and spread to the brain. The safety of this drug will also be studie...
The goal of this clinical research study is to find the highest tolerable dose of WP1066 that can be given to pediatric patients with recurrent (has returned after treatment) cancerous brain tumors or melanoma that has gotten worse and spread to the brain. The safety of this drug will also be studied. WP1066 is designed to target the STAT3 pathway in cancer cells, which makes these cells divide, increases new blood vessels to the tumor, causes the cancer cells to move throughout the body and brain, and avoids them being detected by the immune system. Targeting this pathway may cause the immune system to kill the cancer cells. The investigators will administer five escalating doses of WP1066, starting at lowest dose currently found to be safe and tolerable in adults. WP1066 is not FDA approved or commercially available. It is currently being used for research purposes only. Up to 36 participants will be enrolled in this study. All will take part at Children's Healthcare of Atlanta (CHOA).
Tracking Information
- NCT #
- NCT04334863
- Collaborators
- CURE Childhood Cancer, Inc.
- Peach Bowl LegACy Fund
- Investigators
- Principal Investigator: Tobey MacDonald, MD Emory University
Get Well Soon